Reimbursement for Prostate Cancer Treatment

Ahmed Haddad, Yair Lotan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate cancer (PCa) is a highly prevalent disease with favorable long-term survival in low-risk patients. The majority of PCa patients in the United States receive radical primary treatment in the form of radical prostatectomy or external beam radiation therapy. New technologies have diffused into the field of prostate cancer and have been adopted at a remarkable pace. Most surgery is currently performed robotically and most radiation therapy is delivered with intensity modulated radiation therapy technology. Both advances represent expensive innovative technologies that have limited evidence from prospective randomized studies for superiority over previous generation therapies. Reimbursement for treatment and complex economic considerations are important factors in the dissemination of these technologies. New healthcare legislation will increasingly focus on the cost-effectiveness of new technologies as public scrutiny on healthcare expenditure continues to mount.

Original languageEnglish (US)
Title of host publicationProstate Cancer: Science and Clinical Practice: Second Edition
PublisherElsevier Inc.
Pages367-374
Number of pages8
ISBN (Print)9780128000779
DOIs
StatePublished - Dec 3 2015

Fingerprint

Prostatic Neoplasms
Technology
Radiotherapy
Delivery of Health Care
Therapeutics
Prostatectomy
Health Expenditures
Legislation
Cost-Benefit Analysis
Economics
Prospective Studies
Survival

Keywords

  • Active surveillance
  • Billing
  • Biopsy
  • Cost-effectiveness
  • Cost-utility
  • IMRT
  • Prostate cancer
  • Proton
  • Reimbursement
  • Robotic prostatectomy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Haddad, A., & Lotan, Y. (2015). Reimbursement for Prostate Cancer Treatment. In Prostate Cancer: Science and Clinical Practice: Second Edition (pp. 367-374). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800077-9.00041-4

Reimbursement for Prostate Cancer Treatment. / Haddad, Ahmed; Lotan, Yair.

Prostate Cancer: Science and Clinical Practice: Second Edition. Elsevier Inc., 2015. p. 367-374.

Research output: Chapter in Book/Report/Conference proceedingChapter

Haddad, A & Lotan, Y 2015, Reimbursement for Prostate Cancer Treatment. in Prostate Cancer: Science and Clinical Practice: Second Edition. Elsevier Inc., pp. 367-374. https://doi.org/10.1016/B978-0-12-800077-9.00041-4
Haddad A, Lotan Y. Reimbursement for Prostate Cancer Treatment. In Prostate Cancer: Science and Clinical Practice: Second Edition. Elsevier Inc. 2015. p. 367-374 https://doi.org/10.1016/B978-0-12-800077-9.00041-4
Haddad, Ahmed ; Lotan, Yair. / Reimbursement for Prostate Cancer Treatment. Prostate Cancer: Science and Clinical Practice: Second Edition. Elsevier Inc., 2015. pp. 367-374
@inbook{c1af56ea72ce44c28f9e7be358e140a6,
title = "Reimbursement for Prostate Cancer Treatment",
abstract = "Prostate cancer (PCa) is a highly prevalent disease with favorable long-term survival in low-risk patients. The majority of PCa patients in the United States receive radical primary treatment in the form of radical prostatectomy or external beam radiation therapy. New technologies have diffused into the field of prostate cancer and have been adopted at a remarkable pace. Most surgery is currently performed robotically and most radiation therapy is delivered with intensity modulated radiation therapy technology. Both advances represent expensive innovative technologies that have limited evidence from prospective randomized studies for superiority over previous generation therapies. Reimbursement for treatment and complex economic considerations are important factors in the dissemination of these technologies. New healthcare legislation will increasingly focus on the cost-effectiveness of new technologies as public scrutiny on healthcare expenditure continues to mount.",
keywords = "Active surveillance, Billing, Biopsy, Cost-effectiveness, Cost-utility, IMRT, Prostate cancer, Proton, Reimbursement, Robotic prostatectomy",
author = "Ahmed Haddad and Yair Lotan",
year = "2015",
month = "12",
day = "3",
doi = "10.1016/B978-0-12-800077-9.00041-4",
language = "English (US)",
isbn = "9780128000779",
pages = "367--374",
booktitle = "Prostate Cancer: Science and Clinical Practice: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Reimbursement for Prostate Cancer Treatment

AU - Haddad, Ahmed

AU - Lotan, Yair

PY - 2015/12/3

Y1 - 2015/12/3

N2 - Prostate cancer (PCa) is a highly prevalent disease with favorable long-term survival in low-risk patients. The majority of PCa patients in the United States receive radical primary treatment in the form of radical prostatectomy or external beam radiation therapy. New technologies have diffused into the field of prostate cancer and have been adopted at a remarkable pace. Most surgery is currently performed robotically and most radiation therapy is delivered with intensity modulated radiation therapy technology. Both advances represent expensive innovative technologies that have limited evidence from prospective randomized studies for superiority over previous generation therapies. Reimbursement for treatment and complex economic considerations are important factors in the dissemination of these technologies. New healthcare legislation will increasingly focus on the cost-effectiveness of new technologies as public scrutiny on healthcare expenditure continues to mount.

AB - Prostate cancer (PCa) is a highly prevalent disease with favorable long-term survival in low-risk patients. The majority of PCa patients in the United States receive radical primary treatment in the form of radical prostatectomy or external beam radiation therapy. New technologies have diffused into the field of prostate cancer and have been adopted at a remarkable pace. Most surgery is currently performed robotically and most radiation therapy is delivered with intensity modulated radiation therapy technology. Both advances represent expensive innovative technologies that have limited evidence from prospective randomized studies for superiority over previous generation therapies. Reimbursement for treatment and complex economic considerations are important factors in the dissemination of these technologies. New healthcare legislation will increasingly focus on the cost-effectiveness of new technologies as public scrutiny on healthcare expenditure continues to mount.

KW - Active surveillance

KW - Billing

KW - Biopsy

KW - Cost-effectiveness

KW - Cost-utility

KW - IMRT

KW - Prostate cancer

KW - Proton

KW - Reimbursement

KW - Robotic prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84967166360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967166360&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800077-9.00041-4

DO - 10.1016/B978-0-12-800077-9.00041-4

M3 - Chapter

AN - SCOPUS:84967166360

SN - 9780128000779

SP - 367

EP - 374

BT - Prostate Cancer: Science and Clinical Practice: Second Edition

PB - Elsevier Inc.

ER -